An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Phase of Trial: Phase I/II
Latest Information Update: 14 Nov 2017
At a glance
- Drugs ATYR 1940 (Primary)
- Indications Facioscapulohumeral muscular dystrophy
- Focus Adverse reactions
- Sponsors aTyr Pharma
- 14 Nov 2017 According to an aTyr Pharma media release, in october data was presented at the 22nd International Annual Congress of the World Muscle Society.
- 27 Sep 2017 Results presented in an aTyr Pharma Media Release.
- 27 Sep 2017 According to an aTyr Pharma media release, data will be presented in the upcoming 22nd International Annual Congress of the World Muscle Society 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History